The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.
PlantFuel Life Inc. is a scientifically focused plant-based wellness company managed by a group of successful entrepreneurs who have extensive experience in the areas of consumer packaged goods, manufacturing, logistics, and distribution. FUEL is a CPG life science company focused on the plant-based foods and supplements industry.
Predictmedix AI Inc. is an artificial intelligence ("AI") company developing disruptive and cutting-edge tools for impairment testing and healthcare testing. The Issuer's proprietary technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. The Issuer is also developing cutting edge screening technologies for the healthcare industry. Predictmedix is expanding its proprietary AI technology to screen for infectious diseases, and also to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer’s disease.
PreveCeutical Medical Inc. (CSE: PREV) is a health sciences company that develops innovative options for preventive and curative therapies utilizing nature and nature identical products.
Promino Nutritional Sciences Inc. is a producer, distributor and vendor of consumer packaged nutritional products. Promino's products are widely available, scientifically formulated and clinically proven to help rebuild, restore and rejuvenate muscle.
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief and relaxation, assist with sleeping and to support mood.
Psyence Group Inc. is a science-led global psychedelic platform, led by experts in neurology, neuroscience and drug development. Psyence has built and operates one of the first federally licensed commercial psilocybin cultivation and production facilities. Psyence is pioneering the use of natural psilocybin for the long-term treatment of psychological trauma and its mental health consequences.
Pure Extracts Technologies Corp. is an integrated Canadian plant-based extraction company specializing in the processing of cannabis, hemp and functional mushrooms to produce oils and various derivative products. The company is involved in white labeling activities as well as selling branded oil based products under the Pure Extracts brand.
Quantum BioPharma Ltd. is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented unbuzzd™ and spun it out its OTC version to a company, Celly Nutrition, led by industry veterans. Quantum retains ownership of 25.71% (March 31, 2024) of Celly Nutrition Corp. at www.cellynutrition.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd ™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum retains a large tax loss carry forward of approximately CAD$130 million and could be utilized in the future to offset tax payable obligations against future profits. FSD Pharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical / medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, Quantum BioPharma Strategic Investments Inc., which represent loans secured by residential or commercial property.
RAMM Pharma Corp., through its wholly-owned operating subsidiaries, is engaged in the pharmaceutical and medical product business, and is a leader in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. With RAMM’s large scale cultivation facility, the combined operations are expected to provide for complete vertical integration. Further to its industry leading activities in the cannabis sector, RAMM operates a pharmaceutical, cosmetic and nutraceutical product development and medical services business which has been servicing the local market for 30 years.
Rapid Dose Therapeutics Corp. is a publicly traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries.
Within the cannabis sector, RDT provides a turn-key business solution which enables RDT’s QuickStrip™ proprietary drug delivery technology to be licensed by select partners. RDT’s service-based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. RDT is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs — including humans, animals and plants.
